Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.86 |
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251337 | 1.00 | L3MBTL1 (0.86) | L3MBTL1USP2ALDH1A1POLBLMNA | |
| SCHEMBL2705461 | 0.98 | L3MBTL1 (0.83) | L3MBTL1USP2ALDH1A1POLBLMNA | |
| SCHEMBL5251954 | 0.94 | L3MBTL1 (0.77) | L3MBTL1USP2ALDH1A1POLBLMNA | |
| SCHEMBL10355428 | 0.90 | ATM (0.81) | L3MBTL1USP2ALDH1A1POLBLMNA | |
| SCHEMBL4580893 | 0.90 | ATM (0.81) | L3MBTL1USP2ALDH1A1POLBLMNA | |
| SCHEMBL23043574 | 0.84 | USP2 (0.80) | L3MBTL1USP2ALDH1A1POLBLMNA | |
| SCHEMBL5915299 | 0.84 | ALDH1A1 (1.00) | L3MBTL1ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL5304087 | 0.83 | MAPT (0.87) | L3MBTL1USP2ALDH1A1POLBLMNA | |
| SCHEMBL5915296 | 0.82 | KMT2A (0.66) | L3MBTL1USP2ALDH1A1POLBLMNA | |
| SCHEMBL1020053 | 0.82 | USP2 (0.76) | L3MBTL1USP2ALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758884-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| WO-2005113542-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | BACE1, BACE2, APH1B | L3MBTL1 3594/4885USP2 1491/4885ALDH1A1 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.